Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Watchful waiting wins out for low-risk prostate cancer. A new study spanning three major U.S. healthcare databases found that over the past 15 years, the proportion of low-risk prostate cancer patients receiving no immediate treatment surged dramatically — from about one-third to over four-fifths nationally. Researchers say this shift away from overtreatment should reshape how we think about PSA screening debates.
The way low-risk prostate cancer is managed in the U.S. has undergone a dramatic transformation. A new study published in Cancer, drawing on data from SEER, the VA health system, and the Michigan Radiation Oncology Quality Consortium, found that over the past 15 years, fewer patients are being diagnosed with low-risk disease — and those who are diagnosed are far less likely to receive aggressive treatment.
The shift is striking: active surveillance and watchful waiting have essentially replaced radiation and surgery as the default approach for low-risk cases. Researchers argue this trend directly challenges one of the biggest criticisms of PSA screening — that it leads to overtreatment — since overtreatment itself has plummeted.
By the Numbers:
Why it matters: This population-level shift suggests that the oncology community has largely embraced evidence-based restraint for low-risk prostate cancer. However, researchers caution that residual overtreatment still occurs — particularly in older or sicker men — and warrants continued attention.
